Results 31 to 40 of about 5,563 (240)

UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma [PDF]

, 2023
UMG1 is a unique epitope of CD43, not expressed by normal cells and tissues of haematopoietic and non-haematopoietic origin, except thymocytes and a minority (<5%) of peripheral blood T lymphocytes.
Grillone, Katia, Belmonte, Beatrice, Tuccillo, Franca Maria, Caracciolo, Daniele, Ascrizzi, Serena, Riillo, Caterina, Polerà, Nicoletta, Juli, Giada, Conforti, Francesco, Gulino, Alessandro, Ballerini, Andrea, Signorelli, Stefania, Cirillo, Maria, Migale, Leonardo, Tagliaferri, Pierosandro, Bonelli, Patrizia, Tassone, Pierfrancesco, Pelizon, Cristina, Di Martino, Maria Teresa, Staropoli, Nicoletta   +19 more
core   +1 more source

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment

OncoImmunology, 2021
Novel therapies are needed for effective treatment of AML. In the relapsed setting, prognosis is very poor despite salvage treatment with chemotherapy. Evidence suggests that leukemic stem cells (LSCs) cause relapse.
Hélène Bonnevaux, Stephane Guerif, Jana Albrecht, Erwan Jouannot, Thibaud De Gallier, Christian Beil, Christian Lange, Wulf Dirk Leuschner, Marion Schneider, Cendrine Lemoine, Anne Caron, Céline Amara, Cédric Barrière, Justine Siavellis, Valérie Bardet, Ernesto Luna, Pankaj Agrawal, Donald R. Drake, Ercole Rao, Peter Wonerow, Chantal Carrez, Véronique Blanc, Karl Hsu, Dmitri Wiederschain, Paula G. Fraenkel, Angéla Virone-Oddos   +25 more
doaj   +1 more source

Visualizing Spatial and Stoichiometric Barriers to Bispecific T-Cell Engager Efficacy. [PDF]

Cancer Immunol Res, 2022
Bispecific T-cell engager (BiTE) molecules are biologic T cell–directing immunotherapies. Blinatumomab is approved for treatment of B-cell malignancies, but BiTE molecule development in solid tumors has been more challenging. Here, we employed intravital
You R, Artichoker J, Ray A, Gonzalez Velozo H, Rock DA, Conner KP, Krummel MF.   +6 more
europepmc   +2 more sources

Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report

Journal for ImmunoTherapy of Cancer, 2023
While checkpoint inhibitor therapy has revolutionized the treatment landscape of some solid tumors, it has shown limited efficacy in metastatic castration-resistant prostate cancers (mCRPC).
Michael Lai, Evan Y Yu, Michael T Schweizer, Darien E Reed-Perino   +3 more
doaj   +1 more source

Bispecific T-Cell Engagers Targeting Membrane-Bound IgE [PDF]

Biomedicines, 2021
The increased incidence of allergies and asthma has sparked interest in IgE, the central player in the allergic response. Interaction with its high-affinity receptor FcεRI leads to sensitization and allergen presentation, extracellular membrane-proximal domain in membrane IgE can act as an antigen receptor on B cells, and the interaction with low ...
Aleksandra Rodak, Gerhard Stadlmayr, Katharina Stadlbauer, Dominic Lichtscheidl, Madhusudhan Reddy Bobbili, Florian Rüker, Gordana Wozniak-Knopp   +6 more
openaire   +3 more sources

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies [PDF]

, 2020
The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma.
Locatelli F.
core   +2 more sources

Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro. [PDF]

PLoS One
Cancer immunotherapy, particularly T cell-based therapies, is considered to have strong potential for treating various types of cancer. A promising approach that has emerged is the use of γδ T cell-based strategies for cancer treatment. Neuroblastoma (NB)
Kitidee K, Amonyingcharoen S, Preedagasamzin S, Atjanasuppat K, Sawaisorn P, Srimorkun P, Petvises S, Chaicumpa W, Borwornpinyo S, Anurathapan U, Hongeng S.   +10 more
europepmc   +2 more sources

Shortened Hinge Design of Fab x sdAb-Fc Bispecific Antibodies Enhances Redirected T-Cell Killing of Tumor Cells

Biomolecules, 2022
T cell engager (TCE) antibodies have emerged as promising cancer therapeutics that link cytotoxic T-cells to tumor cells by simultaneously binding to CD3E on T-cells and to a tumor-associated antigen (TAA) expressed by tumor cells. We previously reported
Shuyu Huang, Aina Segués, Martin Waterfall, David Wright, Charlotte Vayssiere, Sander M. J. van Duijnhoven, Andrea van Elsas, Alice J. A. M. Sijts, Dietmar M. Zaiss   +8 more
doaj   +1 more source

TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL

mAbs, 2021
The therapeutic potential of targeting CD19 in B cell malignancies has garnered attention in the past decade, resulting in the introduction of novel immunotherapy agents.
Harbani K. Malik-Chaudhry, Kirthana Prabhakar, Harshad S. Ugamraj, Andrew A. Boudreau, Benjamin Buelow, Kevin Dang, Laura M. Davison, Katherine E. Harris, Brett Jorgensen, Heather Ogana, Duy Pham, Ute Schellenberger, Wim Van Schooten, Roland Buelow, Suhasini Iyer, Nathan D. Trinklein, Udaya S. Rangaswamy   +16 more
doaj   +1 more source

Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy

Haematologica, 2023
T-cell-engaging bispecific antibodies (T-BsAb) have produced impressive clinical responses in patients with relapsed/refractory B-cell malignancies, although treatment failure remains a major clinical challenge. Growing evidence suggests that a complex interplay between immune cells and tumor cells is implicated in the mechanism of action and therefore,
Casey, M, Lee, C, Kwok, WY, Law, SC, Corvino, D, Gandhi, MK, Harrison, SJ, Nakamura, K   +7 more
openaire   +6 more sources